text_1: The cyclin-dependent kinase (CDK) inhibitor roscovitine has been reported to down-regulate the anti-apoptotic protein Mcl-1
text_2: Recent work in model systems and acute myelogenous leukemia has suggested that expression of MCL-1 is a key determinant of resistance to ABT-737